Trials / Completed
CompletedNCT02974855
PF-06741086 Multiple Dose Study in Severe Hemophilia
A MULTICENTER, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF SUBCUTANEOUS OR INTRAVENOUS PF-06741086 IN SUBJECTS WITH SEVERE HEMOPHILIA
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of multiple subcutaneous and/or intravenous doses of PF-06741086 in subjects with severe hemophilia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PF-06741086 | PF-06741086 subcutaneous (SC) injection |
| BIOLOGICAL | PF-06741086 | PF-06741086 SC injection |
| BIOLOGICAL | PF-06741086 | PF-06741086 SC injection |
| BIOLOGICAL | PF-06741086 | PF-06741086 SC injection |
Timeline
- Start date
- 2017-03-08
- Primary completion
- 2018-12-03
- Completion
- 2018-12-03
- First posted
- 2016-11-29
- Last updated
- 2019-12-04
- Results posted
- 2019-12-04
Locations
10 sites across 6 countries: United States, Chile, Croatia, Poland, South Africa, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02974855. Inclusion in this directory is not an endorsement.